Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-16
SponsorChildren's National Research Institute

About this trial

Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.

Eligibility criteria

Qualifiers

diagnosis of SCD

ages 8-16 years

maintained on monthly blood transfusions consistently for at least 3 months.

patients will be proceed to the intervention phase only if they have a T-score > 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score > 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).

Disqualifiers

estimated Intelligence Quotient < 70

motor, visual, or auditory impairment that prevents computer use

known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training

history of photosensitive seizures

Trial design

Treatments tested in this trial

  • EndeavorRx

Treatment groups

20 Participants
are divided into 1 treatment group